Drug Channel Updates

Timely updates on drug shortages, launches, recalls, and more.

Top shortages

Brimonidine Tart 0.2% 5ml Opth Packing and label issues causing this delay.

Diltiazem CP 120mg 30’s Product being allocated by manufacturer.

Diltiazem CP 180mg 30’s Product being allocated by manufacturer.

Diltiazem Cp 240mg 30’s Product being allocated by manufacturer.

Diltiazem Cp 300 mg 30’s Product being allocated by manufacturer.

Dorzlmd/Timol 22.3-6.8mg 10ml Product being allocated and remains in short supply.

Enalapril/Hctz Tb 10-25mg 100’s Issues with red dye during manufacturing. Long-term outlook good.

Levlbutrl Tart HFA 45mcg 15 gm Manufacturing delays causing this issue.

Naltrexone Hcl Tb 50mg 30’s API issues causing delays as well as increased demand.

Quetiapine Fum Tb 200mg 100’s Back-up suppliers are available.

Drug Launches

The latest insights on the drug market.

Recent Launches

Myrbetriq (mirabegron) is a $2.6 billion market but not sure how much product is sold through retail outlets.

Upcoming Launches

Oxtellar XR (oxcarbazepine) is a $210 million market and is scheduled to launch sometime in September. No source vendor has been selected.

Rayos (prednisone) is a $157 million market. Its launch has been delayed many times. No news yet as to when it will launch.

Sandostatin LAR (octreotide acetate) is a $1.5 billion market. Anticipated to launch sometime in the 2nd quarter. Teva is our source vendor.

Sprycel (dasatinib) is a $2.3 billion market. It’s scheduled to launch sometime late September.

Venofer (iron sucrose) is a $927 million market. It’s anticipated to launch sometime in the 2nd quarter of this year.

Victoza (liraglutide recombinant) is a $4.2 billion market and is expected to launch late June. Teva is our source vendor.

Day 181

BromSite (bromfenac sodium drops) is a $30 million market. Lupin will be our source vendor.

Condylox (podofilox gel) is an $11 million market. No update is available. Padagis is the current source vendor.

Indocin OS (indomethacin oral susp) is a $5 million market. ANI will be the source vendor.

Pradaxa (dabigatrain etexilate mesylate) is a $112 million market and will be available to others soon. Apotex will be the source vendor.

Prolensa (bromfenac sodium) is a $186 million market. Lupin will be our source vendor.

Rectiv (nitroglycerin oint) is a $23 million market. Cosette will be our source vendor.

Recalls

The most recent recall information with return forms.

Hospira

Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride, USP Carpuject Units

Reason for recall: Device & Drug Safety – potential packing defect

Company name: Hospira Inc.

Menu